Financial health
- Total debt ($110M) exceeds cash ($61M); net debt is $49M.
- Operating income covered interest expense -18.1× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
CNTA Financials Centessa Pharmaceuticals Plc
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $15M | -$198M | 0.0% | -1384.6% | -$194M | $110M | $61M |
| 2024 | $0 | -$236M | — | — | -$142M | $109M | $383M |
| 2023 | $7M | -$151M | 0.0% | -2499.4% | -$161M | $0 | $128M |
| 2022 | $0 | -$216M | — | — | -$202M | $70M | $394M |
| 2021 | — | -$381M | — | — | -$135M | $76M | $595M |
| 2020 | — | -$11M | — | — | -$11M | $0 | $7M |
| 2019 | — | -$5M | — | — | -$6M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$79M | — | — | — | $110M | $62M |
| Dec '25 | $0 | -$66M | — | — | -$56M | $110M | $61M |
| Sep '25 | $0 | -$55M | — | — | -$59M | $110M | $51M |
| Jun '25 | $0 | -$50M | — | — | — | $110M | $44M |
| Mar '25 | $15M | -$26M | 0.0% | -205.2% | — | $109M | $105M |
| Dec '24 | $0 | -$111M | — | — | -$43M | $109M | $383M |
| Sep '24 | $0 | -$43M | — | — | -$21M | $76M | $395M |
| Jun '24 | $0 | -$44M | — | — | -$41M | $77M | $127M |
| Mar '24 | $0 | -$38M | — | — | -$37M | $77M | $118M |
| Dec '23 | — | -$37M | — | — | -$31M | $0 | $128M |
| Sep '23 | — | -$39M | — | — | -$37M | $74M | $171M |
| Jun '23 | — | -$25M | — | — | -$44M | $73M | $145M |
| Mar '23 | — | -$51M | — | — | -$48M | $72M | $260M |
| Dec '22 | — | -$43M | — | — | -$52M | $70M | $394M |
| Sep '22 | — | -$54M | — | — | -$39M | $68M | $445M |
| Jun '22 | — | -$65M | — | — | -$60M | $67M | $484M |
| Mar '22 | — | -$54M | — | — | -$50M | $75M | $544M |
| Dec '21 | — | -$61M | — | — | -$56M | $76M | $595M |
| Sep '21 | — | -$40M | — | — | -$33M | — | $579M |
| Jun '21 | — | -$41M | — | — | -$34M | — | $614M |
Valuation over time
How the market has priced CNTA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 184.0× (Jan '24) to 418.2× (Jun '26).
P/S
Frequently asked questions
Is CNTA growing its revenue and profit?
See the revenue and net-income charts above for Centessa Pharmaceuticals Plc's multi-year trend.
How much debt does CNTA have?
As of FY2025, Centessa Pharmaceuticals Plc reported $110M of total debt against $61M of cash; operating income covered interest expense -18.1×.
What is CNTA's profit margin?
In FY2025, gross margin was —, operating margin -1384.6%, and net margin -1316.9%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.